We are live on ! Find out more
NEUP icon

Neuphoria Therapeutics

21 hedge funds and large institutions have $5.69M invested in Neuphoria Therapeutics in 2025 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 9 increasing their positions, 1 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,540% more capital inflows, than outflows

Capital inflows: $9.37M | Capital outflows: $571K

800% more repeat investments, than reductions

Existing positions increased: 9 | Existing positions reduced: 1

200% more first-time investments, than exits

New positions opened: 9 | Existing positions closed: 3

40% more funds holding

Funds holding: 15 → 21 (+6)

16.87% more ownership

Funds ownership: 10.39% → 27.26% (+17%)

Holders
21
Holders Change
+6
Holders Change %
+40%
% of All Funds
0.25%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
9
Increased
9
Reduced
1
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

NEUP Hedge Fund Activity: Q4 2025 in Review

21 of the 8,319 institutional investors tracked by Wall St. Rank reported a position in Neuphoria Therapeutics (NEUP) for Q4 2025, worth a combined $5.69M — up 147% from $2.3M a quarter earlier.

Buyers outnumbered sellers: 9 funds opened new NEUP positions and 3 closed out — a net gain of 6 holders — while 9 added to existing stakes and 1 trimmed.

The largest buyer was Lynx1 Capital Management, opening a new position worth an estimated $6.22M. The largest seller was Prosperity Wealth Management, exiting entirely with an estimated $352K sold.

  • 21 institutional investors held Neuphoria Therapeutics (NEUP) as of Q4 2025, up from 15 in Q3 2025.
  • Funds reported $5.69M of Neuphoria Therapeutics stock for Q4 2025, up 147% quarter-over-quarter.
  • 9 funds opened new Neuphoria Therapeutics positions in Q4 2025 and 3 closed out, a net change of +6 holders.
  • The largest Neuphoria Therapeutics buyer in Q4 2025 was Lynx1 Capital Management, an estimated $6.22M added.
  • The largest Neuphoria Therapeutics seller in Q4 2025 was Prosperity Wealth Management, an estimated $352K sold.

Based on aggregated 13F filings for Q4 2025.